Ardelyx Shares Positive Data from Studies of XPHOZAH (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
03.11.2023 - WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical ... Seite 1
Source: wallstreet-online.de